Teva Pharmaceuticals is suing the Centers for Medicare & Medicaid Services (CMS) for its implementation of the drug price negotiation program under the Inflation Reduction Act (IRA). | A new lawsuit from a drug manufacturer,

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

LAVAL, QC - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a pharmaceutical company with a market capitalization of $2.81 billion and impressive revenue growth of 10.91% over the last twelve months,

U.S. division has sued CMS over the Medicare drug pricing negotiations policy included in the Inflation Reduction Act. In its lawsuit filed in D.C. federal court, the Israel-based drugmaker says that guidance CMS has issued on price negotiations "gives the agency even more unchecked price-setting power

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.